DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20194259

Drug price control order: the impact on pharmacoeconomics

Suchi M. Shah, Anil P. Singh, Parth K. Vachhani

Abstract


Background: The objective of the present study was to analyze the prices of metformin, losartan, atorvastatin, paracetamol and aspirin for the doses which are included in the list of Drug Price Control Order (DPCO) 2013.

Methods: Current index medical specialties India, 37th year, April-July 2015 issue was used for analysis. The retail prices of the drugs in INR were tabulated in Microsoft Office Excel 2013. The prices of the above listed drugs were compared with prices of DPCO 2013 for the same doses of drugs. The analysis of drugs costing more than the prices listed in the DPCO with the margin of the difference in percentage was carried out.

Results: Out of 25 brands of metformin 500 mg tablet, 11 (44%) brands had price higher than listed in DPCO 2013. Similarly, prices for losartan 25 mg and 50 mg tablets, 8 (25%) out of 32 and 11 (31.42%) out of 35 were higher respectively. For atorvastatin 5 mg and 10 mg tablets, 2 (9.52%) out of 21 and 8 (13.55%) out of 59 brands had higher prices. For paracetamol 500 mg tablet, 12 (63.15%) out of 19 brands were priced higher than DPCO list. For aspirin 100 mg tablet and 325 mg tablet, 3 (100%) out of 3 brands and 1 (100%) out of 1 brand had higher prices.

Conclusions: Many of the brand formulations have higher prices than the DPCO 2013 issued by government of India. The clinicians prescribing these drugs should be aware of these brand formulations to reduce the cost of the drug therapy.


Keywords


Drug price control order, Price variation, Pharmacoeconomics, Compliance

Full Text:

PDF

References


Indian Pharmaceutical Industry. Available at: https:// www.ibef.org/industry/indian-pharmaceuticals-industry-analysis-presentation. Accessed on 12 April 2019.

Maiti R. Pharmacoeconomics. Postgraduate topics in pharmacology. 1st ed. India: Paras Medical Books Pvt. Ltd; 2013; 203.

Kumar B, Medhi B. Drug Price. In: Medhi B, Prakash A, eds. Advanced pharmacology. Hyderabad: PharmaMed Press; 2014: 138-154.

Kumar R, Kumar N, Ahmad A, Kumar M, Rajendra N, Dixit RK, et al. Cost comparison of antihypertensive drugs available in India with Drugs Prices Control Order price list. Int J Res Med Sci. 2019;7:101-5.

Top 20 generic molecules worldwide. Available at: http://www.fiercepharma.com/special-reports/top-20-generic-molecules-worldwide. Accessed on 12 April 2019.

Current index medical specialties (CIMS) India, 37th year, April-July 2015 issue.

Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12:30-5.

Roy V, Rewari S. Ambiguous drug pricing: a physician’s dilemma. Indian J Pharmacol. 1998;30(6):404-7.

Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15(3):241-50.

Atal S, Deshmankar B, Atal S, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Sci. 2016;8(4):315-21.

Tripathi KD. Aspects of pharmacotherapy, clinical pharmacology and drug development. Essentials of medical pharmacology, 7th ed. Delhi: Jaypee Brothers Medical Publisher (P) Ltd. Inc.; 2013: 71-73.